Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butaselen in Fibrotic Interstitial Lung Disease
CTR20222921Phase 2Completed
- Sponsor
- Shanghai Yuanxi Pharmaceutical Technology
- Start
- Nov 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BS1801 in pulmonary fibrosis (PF), idiopathic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (cHP), Unclassifiable Idiopathic Interstitial Pneumonia, Interstitial Pneumonia With Autoimmune Features (IPAF), sponsored by Shanghai Yuanxi Pharmaceutical Technology. Started Nov 2022; status: completed.
02
Drugs
BS1801
03
Conditions
pulmonary fibrosis (PF)idiopathic nonspecific interstitial pneumonia (NSIP)chronic hypersensitivity pneumonitis (cHP)Unclassifiable Idiopathic Interstitial PneumoniaInterstitial Pneumonia With Autoimmune Features (IPAF)
Beyond the preview
Go deeper on CTR20222921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222921.